3 results
Primary: *To assess if combination therapy of adalimumab and MTX significantly improves the drug survival at one year compared to adalimumab monotherapy in patients with moderate-to-severe psoriasis.Secondary: *To assess if combination therapy of…
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
The primary objective involves the safety of in vivo Raman/scattering during endoscopy. Therefore, we will assess safety parameters (AEs, SAEs, SUSARs). Secondary objective involves the feasibility of the probe-based scattering/(stimulated) Raman…